Glutaminases as a Novel Target for SDHB-Associated Pheochromocytomas/Paragangliomas

• Main Authors: Balazs Sarkadi, Katalin Meszaros, Ildiko Krencz, Letizia Canu, Lilla Krokker, Sara Zakarias, Gabor Barna, Anna Sebestyen, Judit Papay, Zoltan Hujber, Henriett Butz, Otto Darvasi, Peter Igaz, Judit Doczi, Michaela Luconi, Christos Chinopoulos, Attila Patocs
• Format: Article
• Language: English
• Published: MDPI AG 2020-03-01
• Series: Cancers
• Subjects: succinate; sdh; sdhb; pheochromocytoma; paraganglioma; gls-1
• Online Access: https://www.mdpi.com/2072-6694/12/3/599

Pheochromocytoma/paragangliomas (Pheo/PGL) are rare endocrine cancers with strong genetic background. Mutations in the <i>SDHB</i> subunit of succinate dehydrogenase (SDH) predispose patients to malignant disease with limited therapeutic options and poor prognosis. Using a host of cellular and molecular biology techniques in 2D and 3D cell culture formats we show that SDH inhibition had cell line specific biological and biochemical consequences. Based on our studies performed on PC12 (rat chromaffin cell line), Hela (human cervix epithelial cell line), and H295R (human adrenocortical cell line) cells, we demonstrated that chromaffin cells were not affected negatively by the inhibition of SDH either by siRNA directed against <i>SDHB</i> or treatment with SDH inhibitors (itaconate and atpenin A5). Cell viability and intracellular metabolite measurements pointed to the cell line specific consequences of SDH impairment and to the importance of glutamate metabolism in chromaffin cells. A significant increase in glutaminase-1 (GLS-1) expression after SDH impairment was observed in PC12 cells. GLS-1 inhibitor BPTES was capable of significantly decreasing proliferation of SDH impaired PC12 cells. Glutaminase-1 and SDHB expressions were tested in 35 Pheo/PGL tumor tissues. Expression of GLS1 was higher in the SDHB low expressed group compared to SDHB high expressed tumors. Our data suggest that the SDH-associated malignant potential of Pheo/PGL is strongly dependent on GLS-1 expression and glutaminases may be novel targets for therapy.